Wednesday, March 29, 2023


Biotechnology News Magazine


Ampio Pharmaceuticals’ Study Shows Ampion Inhibits a Key Inflammatory Pathway in COVID-19 and Lupus Nephritis

Laboratory results suggest Ampion's suitability for addressing kidney diseases and provides further evidence it is a platform biologic for treatment of inflammatory and autoimmune diseases.

Phase IIb Clincial Trial of Monepantel in Pet Dogs with Treatment Naive B Cell Lymphoma

To date, six dogs with stage 4 to 5 B-cell lymphoma have completed assessments across the five participating trial sites. Treatment of one dog was not in compliance with the dosing instructions (MPL after meal) and that dog was withdrawn from the trial.

Medsenic Announces Positive Results of its Phase II Clinical Study with Arscimed® for the Rx of Chronic Graft Versus Host Disease

The primary endpoint of this prospective Phase II multicenterter, non-randomised study was the improvement of treatment response, i.e., complete or partial disease remission 6 months after GvHD diagnosis, with Arscimed® in combination with prednisone with or without cyclosporine.

Pharmaxis Announces 1st Patient Enrolled in Clinical Trial Studying a Potential New Treatment for Bone Marrow Cancer Myelogibrosis

Pharmaxis has completed site initiation at several Australian and South Korean hospitals and the first patient has been enrolled.

Galapagos and Gilead: Discontinue ISABELA Phase 3 Trials in IPF

February 10, 2021 Galapagos NV and Gilead Sciences decision to halt the ISABELA Phase 3 clinical studies with the investigational autotaxin inhibitor ziritaxestat in patients...

Biophytis Announces Start of Patient Recruitment in Brazil and the USA for Part 2 of the Phase 2-3 COVA Trial

Patient recruitment at most clinical centers in Brazil and the United States will begin for Part 2 of its COVA Study assessing Sarconeos (BIO101) as a potential treatment for acute respiratory failure associated with COVID-19.